Rapid development of seizures and PRES in a COVID-19 patient

Lima, Fabiane Santos de; Klein, Sara; Ammar, Faten El; Wu, Shasha; Rose, Sandra; Tao, James X.; Issa, Naoum P.

doi:10.1016/j.ebr.2021.100436

Cited by 6 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No enhancement. Present NR Discharged P26/M/68 Colombo A et al 8 Hypertensive Present Present Absent Mechanical ventilation NR MRI brain consistent with PRES NR NR Discharged P27/F/57 Colombo A et al 8 Hypertensive Present Absent Present Non-invasive ventilation NR MRI brain consistent with PRES NR NR Discharged P28/F/43 Santos de Lima F et al 41 Normotensive Absent Present Present Mechanical ventilation NR 1st MRI-Area of hyperintensity in the splenium. 2nd MRI- extensive T2/FLAIR hyperintensity in bilateral cererbal hemispheres with mild sulcal enhancement, and gyroform restricted diffusion in right temporooccipito-parietal region.…”

Section: Resultsmentioning

confidence: 99%

Brain MRI findings in COVID-19 patients with PRES: A systematic review

et al. 2022

View full text Add to dashboard Cite

Background Numerous case reports and case series have described brain Magnetic Resonance Imaging (MRI) findings in Coronavirus disease 2019 (COVID-19) patients with concurrent posterior reversible encephalopathy syndrome (PRES). Purpose We aim to compile and analyze brain MRI findings in patients with COVID-19 disease and PRES. Methods PubMed and Embase were searched on April 5th, 2021 using the terms “COVID-19”, “PRES”, “SARS-CoV-2” for peer-reviewed publications describing brain MRI findings in patients 21 years of age or older with evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and PRES. Results Twenty manuscripts were included in the analysis, which included descriptions of 30 patients. The average age was 57 years old. Twenty-four patients (80%) required mechanical ventilation. On brain MRI examinations, 15 (50%) and 7 (23%) of patients exhibited superimposed foci of hemorrhage and restricted diffusion respectively. Conclusions PRES is a potential neurological complication of COVID-19 related disease. COVID-19 patients with PRES may exhibit similar to mildly greater rates of superimposed hemorrhage compared to non-COVID-19 PRES patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Brain MRI findings in COVID-19 patients with PRES: A systematic review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Database search recovered 37 unique articles describing PRES and COVID‐19, of which five were excluded after abstract review. The remaining 32 articles underwent full text review; 22 articles met all inclusion criteria and contained detailed clinical information on 32 individuals with PRES and COVID‐19 [6–27]. All cases reported MRI findings consistent with a diagnosis of PRES (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Persistent visual dysfunction following posterior reversible encephalopathy syndrome due to COVID‐19: Case series and literature review

Hixon

Thaker

Pelak

2021

Euro J of Neurology

View full text Add to dashboard Cite

A growing body of literature has documented the effects of SARS-CoV-2 infection on the central nervous system (CNS), which can range from mild anosmia and dysgeusia to encephalopathy, large vessel strokes, and other reported conditions [1]. Whereas some sequelae appear to be due to direct CNS infection, others may be an indirect effect of the infection-induced severe systemic inflammatory response [1]. Of concern, an increasing number of people with COVID-19, across the spectrum of disease severity, report persistent neurological symptoms weeks to months after the clearance

show abstract

“…need multidisciplinary treatment of pneumonia, VOC, ACS, with supportive care for favorable outcome. 4 (80) 0 (0) Santos de Lima et al [ 117 ] USA 1 (0/1) 43 n/a BT (1) Combination of COVID-19 and SCD may increase risk of posterior reversible encephalopathy syndrome and contribute to higher mortality. n/a 0 (0) Teulier et al [ 118 ] France 1 (1/0) 33 HbSS HU (1) BT (1) SCD patient developed severe ARDS secondary to COVID-19 and was successfully treated with anticoagulation and extracorporeal membrane oxygenation; patient did not develop pulmonary arterial hypertension, suggesting different pathophysiology in SCD pts.…”

Section: Patients With Covid-19 and Sickle Cell Diseasementioning

confidence: 99%